Oncology Views & Analysis

Views & Analysis

Pfizer and the UK cancer landscape: the pharmaphorum podcast

Pfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK cancer landscape.

Views & Analysis

Q&A: Avacta’s Amrik Basran on immunotherapy

Dr Amrik Basran from Avacta explains the current state of cancer immunotherapy and the challenges of moving into combinations of these innovative treatments.

Views & Analysis

Demonstrating the value of RWE

A new cross-industry effort hopes to research the benefits of RWE and promote acceptance of alternatives to traditional trials.

Views & Analysis

QandA-Drapers-Jenna-Balestrini-on-the-future-of-CAR-T

Q&A: Draper’s Jenna Balestrini on the future of CAR-T

As exciting as CAR-T is, there are still myriad challenges preventing it from reaching its full potential.

Views & Analysis

The state of personalised medicine in 2019

Things are good, and they’re getting better.

Views & Analysis

ESMO 2019 roundup

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma companies choosing it as a forum to reveal their latest studies.

Pfizer and the UK cancer landscape: the pharmaphorum podcast

Q&A: Avacta’s Amrik Basran on immunotherapy

Demonstrating the value of RWE

Q&A: Draper’s Jenna Balestrini on the future of CAR-T

The state of personalised medicine in 2019

ESMO 2019 roundup

Zuckerberg, Chan's Biohub launches protein 'world model'

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks